<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e>/reperfusion injury ends up in the cascade of excitotoxic stimulation of <z:chebi fb="1" ids="18421">superoxide</z:chebi> and nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> formation leading to the generation of highly reactive products, including peroxinitrite and <z:chebi fb="1" ids="29191">hydroxyl radical</z:chebi>, which are capable of damaging <z:chebi fb="23" ids="18059">lipids</z:chebi>, proteins and DNA </plain></SENT>
<SENT sid="1" pm="."><plain>Several polyphenolic compounds scavenge the radicals and protect from injury </plain></SENT>
<SENT sid="2" pm="."><plain>5,7,3',4',5'-pentahydroxy dihdroflavanol-3-O-(2''-O-galloyl)-beta-d-glucopyranoside (AP1), a polyphenolic compound, isolated from Anogeissus pendula Edgew was tested for its neuroprotective effect in transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
<SENT sid="3" pm="."><plain>Transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was produced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 2h for studying <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, <z:hpo ids='HP_0002181'>brain edema</z:hpo>, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>AP1 was tested for in vitro protection from <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> and <z:chebi fb="17" ids="16240">hydrogen peroxide</z:chebi>-induced damage to Neuro-2a cells by <z:chebi fb="0" ids="53233">MTT</z:chebi> assay </plain></SENT>
<SENT sid="5" pm="."><plain>It was also tested for its in vitro <z:chebi fb="11" ids="22586">antioxidant</z:chebi>, <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation inhibition, NO scavenging and cyclooxygenase inhibitory activities </plain></SENT>
<SENT sid="6" pm="."><plain>AP1 treatment (30 mg/kg i.p.) before reperfusion injury (0 h) significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, <z:hpo ids='HP_0002181'>cerebral edema</z:hpo>, number of apoptotic cells in penumbra and neurobehavioural abnormality score and <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation, protein <z:chebi fb="1" ids="23019">carbonyl</z:chebi> levels and total <z:chebi fb="0" ids="29256">thiols</z:chebi> in brain </plain></SENT>
<SENT sid="7" pm="."><plain><z:mp ids='MP_0011593'>Increased catalase activity</z:mp> and NOx levels in ischemic animals were significantly reduced by AP1 treatment </plain></SENT>
<SENT sid="8" pm="."><plain>AP1 (3 microg/ml) protected Neuro-2a cells to <z:chebi fb="0" ids="30492">H2O2</z:chebi> and <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi>-induced damage </plain></SENT>
<SENT sid="9" pm="."><plain>In in vitro studies, AP1 was found to possess reducing and NO scavenging activities </plain></SENT>
<SENT sid="10" pm="."><plain>It also reduced <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation and inhibited cyclooxygenase activity (cyclooxygenase-1 and cyclooxygenase-2) </plain></SENT>
<SENT sid="11" pm="."><plain>AP1 can be used as a neuroprotective agent in <z:hpo ids='HP_0001297'>stroke</z:hpo> as it <z:mp ids='MP_0006043'>reduced apoptosis</z:mp> and found to be a good <z:chebi fb="11" ids="22586">antioxidant</z:chebi> and anti-inflammatory compound </plain></SENT>
</text></document>